1 result(s) for LGX818
|PI Name||Protocol #||Title|
|Matthew Taylor||IRB00010630||CLGX818X2109: The LOGIC 2 trial, A phase II, multi-center, open-label study of sequential LGX818/MEK162 combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally advanced or metastatic BRAF V600 melanoma|
You may also qualify for Phase 1 Program trials.
For more information: